WILMINGTON — Incyte has announced promising results from a third phase of a trial studying Monjuvi, including more than half of the patients in the drug study showing meaningful improvement in follicular lymphoma.
Monjuvi, also known as tafasitamab, is a monoclonal antibody used in a combination therapy for treating adults with relapsed or refractory diffuse large B-cell lymphoma, a cancer…
…
Continue reading this article at;
https://delawarebusinesstimes.com/news/incyte-reveals-promising-results-for-monjuvi-trial/
delawarebusinesstimes.com
Feed Name : Delaware Business Times
Bioscience & Pharmaceutical,New Castle County,News,Monjuvi
hashtags : #Incyte #reveals #promising #results #Monjuvi #trial